Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates
- 10 December 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in Mycopathologia
- Vol. 188 (1-2), 9-20
- https://doi.org/10.1007/s11046-022-00694-x
Abstract
Introduction Fungal co-infections are considered an important complication in hospitalized patients with SARS-CoV-2 that can be attributed to disease aggravation, increased mortality, and poor outcomes. This study was conducted to determine the species distribution and antifungal susceptibility patterns of Candida isolates from hospitalized COVID-19 patients in Shiraz, Iran, in addition to associated risk factors and outcomes of co-infections with Candida species. Materials and Methods In this single-center study, a total of 106 hospitalized COVID-19 patients were evaluated for clinical characteristics and outcomes. Species identification was performed by ITS1-5.8S-ITS2 gene sequencing. Antifungal susceptibility testing to fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, amphotericin B, and nystatin was determined according to the M27-A3/S4 CLSI protocol. Results Candida species were recovered from 48% (51/106) of hospitalized COVID-19 patients. Statistical analysis showed that patients who had heart failure, bacterial co-infection, and were receiving empirical antifungal therapy had a higher risk of developing Candida co-infection. In total, 71 Candida isolates were recovered, of which C. albicans (69%) was the most prevalent isolate. The majority of the Candida isolates were susceptible to all classes of tested antifungal drugs. Discussion Our results elucidate a high rate of Candida co-infections among hospitalized COVID-19 patients. Comorbidities such as heart failure, HTN, COPD, bacterial infections as well as therapeutic interventions including catheterization, mechanical ventilation, and ICU admission increased the risk of Candida spp. isolation from the bloodstream, respiratory tract and urine samples, which led to a higher in-hospital mortality rate. Additionally, obtained data clarified that empirical antifungal therapy was not as successful as anticipated.Keywords
Funding Information
- Vice-Chancellor for Research, Shiraz University of Medical Sciences (26040)
This publication has 64 references indexed in Scilit:
- The Susceptibility Patterns of Candida Species Isolated From Urine Samples to Posaconazole and CaspofunginJundishapur Journal of Microbiology, 2015
- Consensus guidelines for the use of empiric and diagnostic‐driven antifungal treatment strategies in haematological malignancy, 2014Internal Medicine Journal, 2014
- Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff ValuesMycopathologia, 2014
- Susceptibility of Candida species isolated from immunocompromised patients to antifungal agents.Eastern Mediterranean Health Journal, 2011
- Candida albicans Interactions with Bacteria in the Context of Human Health and DiseasePLoS Pathogens, 2010
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Differentiation of Candida albicans and Candida dubliniensis Using a Single-Enzyme PCR-RFLP MethodJapanese Journal of Infectious Diseases, 2005
- The immune response to fungal infectionsBritish Journal of Haematology, 2005
- Candida Colonization and Subsequent Infections in Critically III Surgical PatientsAnnals of Surgery, 1994
- Yeast Colonization and Drug Susceptibility Pattern in the Pediatric Patients With NeutropeniaJundishapur Journal of Microbiology, 1970